Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original). A compound according to the general Formula (I)

the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein

- n is an integer, equal to 0, 1 or 2;
- p is an integer equal to 1 or 2;
- g is an integer equal to 0 or 1;
- O is O or NR³;
- X is a covalent bond or a bivalent radical of formula -O-, -S- or $-NR^3-$;
- each R³ independently from each other, is hydrogen or alkyl
 ;
- each R^1 independently from each other, is selected from the group of Ar^1 , Ar^1 -alkyl and di(Ar^1)-alkyl;
- R² is Ar², Ar²-alkyl, di(Ar²)alkyl, Het¹ or Het¹-alkyl;
- Y is a covalent bond or a bivalent radical of formula C(=0)-,- SO_2 -, >C=CH-R or >C=N-R, wherein R is CN or nitro ;
- each Alk represents, independently from each other, a covalent bond; a bivalent straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 6 carbon atoms; or a cyclic saturated or

unsaturated hydrocarbon radical having from 3 to 6 carbon atoms; each radical optionally substituted on one or more carbon atoms with one or more alkyl, phenyl, halo, cyano, hydroxy, formyl and amino radicals;

- is selected from the group of hydrogen, alkyl, alkyloxy, Ar³-oxy, alkyloxycarbonyl, alkylcarbonyloxy, mono- and di(alkyl)amino, mono-and di(Ar³)amino, mono-and di(alkyloxycarbonyl)amino, Ar³, Ar³carbonyl, Het² and Het²carbonyl;
- Ar¹ is phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, alkyl, cyano, aminocarbonyl and alkyloxy;
- Ar² is naphtalenyl or phenyl, each optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of halo, nitro, amino, mono- and di(alkyl)amino, cyano, alkyl, hydroxy, alkyloxy, carboxyl, alkyloxycarbonyl, aminocarbonyl and mono- and di(alkyl)aminocarbonyl;
- is naphthalenyl or phenyl, optionally substituted with 1, 2 or 3 substituents, each independently from each other, selected from the group of alkyloxy, alkyl, halo, hydroxy, pyridinyl, morpholinyl, pyrrolidinyl, imidazo[1,2-a]pyridinyl, morpholinylcarbonyl, pyrrolidinylcarbonyl, amino and cyano;
- Het is a monocyclic heterocyclic radical selected from the the group of pyrrolyl, pyrazolyl, imidazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl; or a bicyclic heterocyclic radical selected from the group of quinolinyl, quinoxalinyl, indolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl; each heterocyclic

radical may optionally be substituted on any atom by a radical selected from the group of halo and alkyl;

Het² is a monocyclic heterocyclic radical selected from the group of pyrrolidinyl, dioxolyl, imidazolidinyl, pyrrazolidinyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, imidazolidinyl, tetrahydrofuranyl, 2H-pyrrolyl, pyrrolinyl, imidazolinyl, pyrrazolinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl and triazinyl;

- or a bicyclic heterocyclic radical selected from the group of benzopiperidinyl, quinolinyl, quinoxalinyl, indolyl, isoindolyl, chromenyl, benzimidazolyl, imidazo[1,2-a]pyridinyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzofuranyl and benzothienyl;
- each radical optionally substituted with one or more radicals selected from the group of Ar¹, Ar¹alkyl, halo, hydroxy, alkyl, piperidinyl, pyrrolyl, thienyl, oxo, alkyloxy, alkyloxyalkyl and alkyloxycarbonyl; and

alkyl is a straight or branched saturated hydrocarbon radical having from 1 to 6 carbon atoms or a cyclic saturated hydrocarbon radicals having from 3 to 6 carbon atoms; optionally substituted on one or more carbon atoms with one or more radicals selected from the group of phenyl, halo, cyano, oxo, hydroxy, formyl and amino.

```
2. (Original) A compound according to claim 1, characterized in that
   is 1 ;
n
  is 1 ;
m
  is 1 ;
  is 0 ;
q
Q
  is 0 ;
X is a covalent bond;
each R<sup>1</sup> is Ar<sup>1</sup> or Ar<sup>1</sup>-alkyl;
R^2 is Ar^2;
   is a covalent bond or a bivalent radical of formula -
       C(=0) - or -SO_2 - ;
             represents, independently from each other, a
each Alk
       covalent bond; a bivalent straight saturated
       hydrocarbon radical having from 1 to 6 carbon atoms;
       each radical optionally substituted on one or more
       carbon atoms with one or more phenyl radicals;
        is selected from the group of hydrogen, alkyl, mono-
L
       and di(alkyloxycarbonyl)amino, Ar3 and Het2;
Ar<sup>1</sup> is phenyl;
Ar<sup>2</sup> is phenyl, each optionally substituted with 1,2 or 3
       alkyl substituents;
Ar^3
        is phenyl, optionally substituted with 1 or 2
       substituents, each independently from each other
       selected from the group of halo and cyano ;
        is a monocyclic heterocyclic radical selected from
Het<sup>2</sup>
       the group of tetrahydrofuranyl, pyrrolidinyl,
       pyrazolyl, furanyl, thienyl, pyrimidinyl,
       thiadiazolyl and pyridinyl; each radical optionally
       substituted with one or more alkyl or
       alkyloxycarbonyl radicals; and
         is a straight saturated hydrocarbon radical having from
alkyl
1 to 6 carbon atoms or a cyclic saturated hydrocarbon
       radicals having from 3 to 6 carbon atoms.
```

3. (Currently Amended) A compound according to claim 1 any

- of claim[s] 1[2, characterized in that] wherein R^1 is Ar^1 methyl and attached to the 2-position or R^1 is Ar^1 and attached to the 3-position.
- 4. (Currently Amended) A compound according to claim 1 any of any of claim[s] 1[3">any characterized in that the wherein R²-X-C(=Q) moiety is 3,5-di-(trifluoromethyl) phenylcarbonyl.
- 5. (Currently Amended) A compound according to claim 1 any of claim[s] 1[-4, characterized in that] wherein p is 1.
- 6. (Currently Amended) A compound according to <u>claim 1</u> any of <u>claim[s] 1[5, characterized in that</u>] wherein Y is -C(=0)-.
- 7. (Currently Amended) A compound according to claim 1
 any of claim[s] 1[6, characterized in that] wherein Alk is a covalent bond.
- 8. (Currently Amended) A compound according to claim 1 any of claim[s] 1[-7, characterized in that] wherein L is Het².
- 9. (Currently Amended) A compound selected from the group of compounds with compound number 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22 as mentioned described in Table 1.
- 10. (Currently Amended) A compound according to any one of claims 1 9 Claim 1 for use as a medicine.
- 11. (Cancelled)
- 12. (Currently Amended) The use of a compound according to claim 1 11 for the manufacture of a medicament for treating schizophrenia, emesis, anxiety, depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pain,

neurogenic inflammation, asthma, micturition disorders such as urinary incontinence and nociception.

- 13. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound according to any one of claims 1 9 of Claim 1.
- 14. (Currently Amended) A process for preparing a pharmaceutical composition as claimed in claim 13, characterized in that a comprising mixing a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as claimed in any one of claims 1 9 of Claim 1.
- 15. (Original) A process for the preparation of a compound of Formula (I'') in which an intermediate compound of Formula (II) is reacted with an intermediate compound of Formula (III), wherein the radicals R², X, Q, R¹, m, n, p and q are as defined in claim 1.

$$\begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \\ \end{array} \end{array} \end{array} \end{array} \begin{array}{c} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \end{array} \begin{array}{c} \\ \\ \\ \\ \end{array} \begin{array}{$$

16. (Original) A process for the preparation of a compound of Formula (I') in which a final compound of Formula (I'') is reductively hydrogenated, wherein the radicals R², X, Q, R¹, m, n, p and q are as defined in claim 1.

- 17. (Original) A process for the preparation of a compound according to Formula (I') comprising the consecutive steps of
 - 1) obtaining a compound of Formula (I'') according to claim 15;
 - 2) obtaining a compound of Formula (I') according to claim 16.